1. Home
  2. IOVA vs ASST Comparison

IOVA vs ASST Comparison

Compare IOVA & ASST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$4.08

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

ASST

Asset Entities Inc. Class B

HOLD

Current Price

$15.15

Market Cap

1.3B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
IOVA
ASST
Founded
2007
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
2008
2022

Fundamental Metrics

Financial Performance
Metric
IOVA
ASST
Price
$4.08
$15.15
Analyst Decision
Buy
Strong Buy
Analyst Count
10
4
Target Price
$9.00
$23.50
AVG Volume (30 Days)
12.1M
4.8M
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
14.84
82.56
EPS
N/A
N/A
Revenue
N/A
$633,489.00
Revenue This Year
$47.74
$294.91
Revenue Next Year
$40.31
$12.16
P/E Ratio
N/A
N/A
Revenue Growth
N/A
128.67
52 Week Low
$1.67
$0.49
52 Week High
$5.63
$19.75

Technical Indicators

Market Signals
Indicator
IOVA
ASST
Relative Strength Index (RSI) 53.47 47.11
Support Level $2.07 $14.32
Resistance Level $4.35 $17.89
Average True Range (ATR) 0.36 1.24
MACD -0.02 -0.36
Stochastic Oscillator 40.45 29.47

Price Performance

Historical Comparison
IOVA
ASST

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

About ASST Asset Entities Inc. Class B

Strive Inc is a structured finance company and institutional asset manager focused on disciplined capital allocation and long term value creation. The company has adopted bitcoin as its hurdle rate for capital deployment because of its fiduciary duty to maximize long-term value for stockholders, and compounding purchasing power over time. It operates in two reportable operating segments: the Asset Management segment, which provides investment advisory services and the Corporate & Other segment, which includes the company's bitcoin treasury operations. The majority of the revenue is derived from the Asset Management segment.

Share on Social Networks: